NAHP: What It Reveals About Propylene Oxide Exposure
REVIEWED BY
William Maish, MD MBA MPH
Clinical Product Lead
Published
Last updated
Key takeaway:
This urine test measures NAHP (2-HPMA), a biomarker of propylene oxide exposure from sources like tobacco smoke, e‑cig aerosols, certain workplaces, and some consumer products. Identifying elevated exposure early helps you reduce risks such as respiratory irritation, headaches, and longer-term cancer risk.
NAHP is a urinary “mercapturic acid” metabolite that forms when your body detoxifies propylene oxide, a small, highly reactive epoxide used to sterilize medical equipment and some foods and to make polyurethane and other chemicals. Propylene oxide can also be present in tobacco smoke and certain industrial or warehouse air. People are mainly exposed by inhalation in workplaces or enclosed spaces; smaller amounts may come from ingestion of foods that have been treated for microbial control. Labs typically measure NAHP in urine, often adjusted for creatinine. Because this metabolite clears relatively quickly, a single result reflects recent exposure — generally the last day or two.
Why propylene oxide exposure is worth quantifying
Why it matters: propylene oxide is an alkylating agent that readily reacts with biological molecules. At sufficient doses it can irritate eyes and airways, and in animal studies it has shown genotoxic potential. Regulatory and expert groups classify it as a probable human carcinogen, though typical community exposures are much lower than in industrial settings. Your body conjugates propylene oxide with glutathione, then processes it to NAHP and excretes it in urine. That makes NAHP a practical, near‑term readout of exposure without needing to measure the parent gas directly. The goal is balanced: not alarm, but visibility — letting you see whether propylene oxide is likely part of your current exposure landscape.
Thanks for signing up!
Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.
Who tends to benefit from an NAHP test
Propylene oxide’s biology connects to real‑world questions. If you work in sterilization, foam or resin manufacturing, warehousing near fumigated goods, or are frequently around tobacco smoke, this epoxide can contact your eyes and airways and add oxidative and irritation stress. Measuring NAHP helps distinguish incidental contact (a brief whiff during a one‑time task) from sustained exposure (repeated or daily contact), which is what tends to matter for symptoms and long‑term risk. Because the metabolite reflects recent exposure, a result that stays low across repeated tests suggests routine exposure is limited; elevations that persist over time suggest a meaningful ongoing source. Testing can be especially informative before or during pregnancy, in fertility planning, or when you’re troubleshooting headaches, sore throat, cough, or unexplained fatigue in a high‑exposure setting.
Reading an NAHP result
Relatively low NAHP usually means limited recent contact with propylene oxide and a lower likelihood of short‑term airway or eye irritation from this specific epoxide. Non‑smokers outside of industrial settings often land here. In pregnancy and early childhood, lower exposures are particularly desirable because developing tissues are more vulnerable to oxidative and inflammatory stress, and epoxides can cross biological barriers, though everyday levels in the general population are usually low.
Relatively higher NAHP points to recent or ongoing exposure — common examples include regular tobacco smoke exposure or work around sterilization processes or foams. When elevated, the systems doing extra work are primarily the airways and the liver’s detox pathways that handle glutathione conjugation and clearance. Symptoms, if present, often show up where this toxin contacts or stresses tissue first: eyes, nose, throat, and sometimes nonspecific fatigue or headache after work shifts. Because the metabolite clears within about a day or two, persistent elevations across multiple tests tend to reflect a repeating source rather than a single encounter.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Labs report NAHP in urine, often normalized to creatinine to account for hydration. Reference intervals are typically population‑based — what most people without known high exposures fall into. For environmental toxins, lower values are generally preferable when feasible, and a clinician's interpretation improves when you know what you were doing in the prior 24–48 hours. A second measurement after typical routines can confirm whether a higher reading was a one‑off or part of your baseline.
What to pair with NAHP results
Big picture: a single environmental toxin marker rarely tells the whole story. Patterns across multiple exposure markers, plus general health labs and your lived context, provide the best picture of risk over time. Think of NAHP like checking your step count from yesterday — useful, but more powerful as a trend. Repeat results, paired with symptom timelines and known exposures, help separate transient spikes from persistent patterns and guide sensible next steps with your clinician.
Frequently Asked Questions
This test measures N‑acetyl‑S‑(2‑hydroxypropyl)‑L‑cysteine (NAHP), a mercapturic acid metabolite and urinary exposure marker rather than the parent compound. It reflects recent exposure to propylene oxide and related epoxide electrophiles and is used in biomonitoring because these reactive chemicals are detoxified by glutathione conjugation to form NAHP for excretion. Elevated urinary NAHP indicates uptake and biotransformation of alkylating epoxides that can interact with cellular macromolecules.
Testing clarifies recent internal exposure, helps track whether mitigation steps (ventilation, avoiding sources, workplace controls, smoking cessation) reduce body burden, and guides prioritization of further evaluation or interventions for detox optimization.
Who benefits most: people with occupational or high environmental exposure risk (plastics or chemical industry workers), smokers or those with household smoke exposure, individuals with unexplained respiratory/dermatologic/systemic symptoms, people concerned about fertility or thyroid effects, and those actively optimizing detox capacity or longevity — useful for clinicians and environmental health assessments but presented here as informational rather than prescriptive.
A typical approach is to obtain a baseline test once to assess exposure to N-Acetyl (2-Hydroxypropyl) cysteine (NAHP); if levels are elevated, perform periodic follow-up testing (for example, every 3–12 months or as recommended by your clinician) and retest after any significant lifestyle or environmental changes—for example, "after changing household products" or "following detoxification efforts."
NAHP test results can be affected by the timing of sample collection (levels vary with time since exposure), recent exposure sources (contaminated food, air, drinking water or consumer products), individual metabolism (age, genetics, liver function and other physiological differences), hydration status (dilution concentrates or lowers urinary values), and the sample type collected (urine versus blood yield different concentrations and windows of detection); additionally, certain medications or dietary supplements can alter NAHP readings.
Fasting is generally not required for NAHP testing; many labs use urine samples and do not mandate fasting. Some laboratories prefer a first‑morning void because it can be more concentrated, but requirements vary—follow the specific instructions provided by the testing facility.
To reduce confounding, avoid nonessential recent exposures to potential sources of NAHP or related chemicals—examples include handling certain plastics, solvents, pesticides, or heavy use of personal care products—immediately before sampling when practical. Note and report any recent product use or environmental/occupational contact (plastics, personal care items, pesticides, chemicals at work, etc.) on the sample form or to the clinician, as this information helps interpret results.
The NAHP concentration typically reflects recent exposure and short-term metabolic/excretory burden rather than long-term total body burden, so timing of the sample relative to exposure is critical (e.g., spot urine vs 24‑hour collections yield different interpretive value). Consistent collection procedures, appropriate timing, and use of mass‑spectrometry based methods maximize accuracy; clinical interpretation should consider exposure history and other biomarkers.
High NAHP levels usually mean your body has been exposed to more of the chemical(s) that break down into NAHP or that your body is clearing the chemical more slowly. That can happen after recent or ongoing environmental or occupational exposure (air, dust, products, or certain workplace chemicals), from lifestyle sources like smoking, or because of individual differences in metabolism or impaired liver/kidney clearance. Elevated levels raise concern about a higher internal “body burden,” but a single high result does not by itself prove disease or predict specific health effects.
Results must be interpreted together with other toxin measurements, lifestyle information, and health markers rather than in isolation. Low NAHP generally suggests low exposure or faster clearance. If levels are outside the reference range, consider reviewing possible exposure sources, repeating testing for confirmation, and discussing follow-up or monitoring with your healthcare provider to decide whether further evaluation (exposure reduction, additional biomonitoring, or organ-function tests) is needed.
NAHP is a mercapturic acid–type metabolite measured in urine that reflects the body’s recent processing of certain electrophilic or reactive chemicals through glutathione conjugation. A higher-than-reference NAHP result generally suggests recent exposure to a compound that is detoxified via this pathway or an increased rate of conjugation; a low or undetectable result may reflect low exposure or, less commonly, impaired conjugation capacity. Exact meaning depends on the laboratory’s reference range, the units reported, and whether the sample was spot urine or a timed collection.
Interpret results in the context of how the sample was reported: many urine toxicant metabolites are normalized to creatinine (or reported as µg/g creatinine) to account for dilution, and timing relative to suspected exposure matters because mercapturates are usually cleared within hours to days. Single measurements are less informative than serial measurements—trends (rising, falling or stable levels) better indicate ongoing exposure, clearance after avoidance or changes in metabolic handling.
Always review NAHP alongside related toxin markers and relevant body-system indicators (for example, other mercapturate metabolites, liver and kidney function tests, and oxidative-stress or glutathione-related biomarkers) and interpret results in the context of known exposures, symptoms, and occupational or environmental history. If findings are unexpected or concerning, discuss them with a clinician or toxicology specialist who can integrate the lab data with clinical context and recommend follow-up testing or exposure-reduction steps.
